Coherus Oncology (CHRS) Change in Account Payables (2013 - 2026)
Coherus Oncology (CHRS) reported Change in Account Payables of $2.6 million for Q1 2026, down 80.34% on a YoY basis from $13.0 million in Q1 2025, and up 150.39% sequentially from -$5.1 million in Q4 2025.
Coherus Oncology (CHRS) Change in Account Payables (2013 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 14 years of Change in Account Payables data on file, last reported at $2.6 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 80.34% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at -$30.0 million (down 453.84% YoY), and the FY2025 full-year result was -$19.6 million, down 396.6% from the prior year.
- Change in Account Payables improved to $2.6 million in Q1 2026, from -$5.1 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $39.5 million in Q2 2024 to a low of -$50.4 million in Q3 2024.
- A 5-year average of -$101058.8 and a median of $1.6 million in 2022 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables surged 2243.35% in 2022 and tumbled 845.04% in 2024, its largest moves.
- Tracing CHRS's Change in Account Payables over 5 years: stood at $1.6 million in 2022, then tumbled by 149.03% to -$785000.0 in 2023, then soared by 907.9% to $6.3 million in 2024, then slumped by 180.23% to -$5.1 million in 2025, then soared by 150.39% to $2.6 million in 2026.
- Business Quant data shows CHRS's Change in Account Payables at $2.6 million in Q1 2026, -$5.1 million in Q4 2025, and -$15.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | 2.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.56 Mn |
| Mar 31, 2026 | 2.56 Mn |
| Dec 31, 2025 | -5.09 Mn |
| Dec 31, 2025 | -5.09 Mn |
| Sep 30, 2025 | -15.30 Mn |
| Sep 30, 2025 | -15.30 Mn |
| Jun 30, 2025 | -12.21 Mn |
| Jun 30, 2025 | -12.21 Mn |
| Mar 31, 2025 | 13.04 Mn |
| Mar 31, 2025 | 13.04 Mn |
| Dec 31, 2024 | 6.34 Mn |
| Dec 31, 2024 | 6.34 Mn |
| Sep 30, 2024 | -50.36 Mn |
| Sep 30, 2024 | -50.36 Mn |
| Jun 30, 2024 | 39.46 Mn |
| Jun 30, 2024 | 39.46 Mn |
| Mar 31, 2024 | 616,000.00 |
| Mar 31, 2024 | 616,000.00 |
| Dec 31, 2023 | -785,000.00 |
| Dec 31, 2023 | -785,000.00 |